References
Chuang-Stein, C. (2004)."Seize the opportunities." Pharmaceutical Statistics. 3, 157–159.
DiMasi, J., Hansen, R.W., Grabowski, H.G. (2003). "The price of innovation: new estimates of drug development costs." Journal of Health Economics. 22, 151–185.
"FDA 'Critical Path' May Lead To Changes In Dosing, Active-Control Trials." December 13, 2004. Pink Sheet. 31.
Grieve, A. (2002). "Do statisticians count? A personal view."Pharmaceutical Statistics. 1, 35–43.
International Conference of Harmonization of Pharmaceuticals for Human Use (ICH) E9. (1998). "Statistical Principles for Clinical Trials." Available at http://www.ich.org.
Lendrem, D. (2002). "Statistical support to non-clinical."Pharmaceutical Statistics. 1, 71–73. Pharmaceutical ...
Get Pharmaceutical Statistics Using SAS now with the O’Reilly learning platform.
O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.
